Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
about
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosisC-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancerInsidious changes in stromal matrix fuel cancer progressionCytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro.Clinical relevance of biologic factors in male breast cancer.Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.Circulating tumor markers in breast cancer: accepted utilities and novel prospects.Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.Serpins promote cancer cell survival and vascular co-option in brain metastasisObesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extractsIncrease in the circulating level of hepatocyte growth factor in gastric cancer patients.Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.Development of a new metastatic human breast carcinoma xenograft line.Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic functionExpression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancerTumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer.Emerging biomarkers in breast cancer care.PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively.The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO2 pneumoperitoneum.Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.Transforming growth factor-beta in breast cancer: a working hypothesis.Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models are Promoted by PELP1/AIB1 Complexes.Assessing Tumor Angiogenesis in Histological Samples.Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group.Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
P2860
Q24319106-9B6DDD54-22BA-47E6-9427-9E947D2CC4A0Q24795406-BACB214A-344B-4E8B-9283-2BB460AF33E1Q26851261-9B4FC435-5304-4EFB-A5EE-57B02F34E4DFQ33178835-AF8CE1DB-BAC6-4031-9AA2-5FC0BF390DE4Q33183149-8A14BC3B-87E5-4760-8770-26DD31B887CBQ33186595-7C8AE806-E134-4DAA-819E-E3FEECB1CA06Q33255953-B63D8F35-EEED-46C3-94FC-89AF1DA7F6BFQ33538432-776CA845-C753-4043-B436-3F844730DE27Q33538453-632E70A9-92A3-4F04-AE84-277CDE8829DAQ33676610-91153B71-777B-4741-9C83-18E8816DCD34Q34407528-29E29561-4002-47F4-BE56-8452861BA108Q34996841-50310299-A4DF-4D3E-9E3E-3684D1FEB180Q36114789-14A58F52-5B97-40C6-9C63-23F9BC673870Q36115751-F0927EE5-C14C-4BCB-BC23-6DFEE337D081Q36116145-75E747BF-4A3D-4B1C-BBF2-862169E0C918Q36214635-EDAA315A-03AE-4F13-A137-23938345A75DQ36291662-AE3F5B2C-A5C3-4465-A99C-7CADCA02ED4FQ36430945-AABA62A3-5B8A-4E80-82B2-B19EEFE6A6CEQ36431096-A0891A54-877A-4E00-8425-49E04B411555Q36486880-334330DC-A9B5-46BE-AFF3-B0DED4A68D23Q36618953-AAB1EDDA-FF24-4366-B7B4-771CC94A9990Q36761523-01850975-3C93-4241-85B5-BD3ACF64268AQ36840119-EC465443-7C9F-4A44-8A13-B08C0489CD77Q36896141-62AAF3BE-0763-4937-8EAC-A70CD4507B20Q37779305-B153609D-02CD-40F8-9342-475FC3059416Q38462629-315329A0-F332-45FB-A44B-7947B3EDDA95Q39565683-1CE0E146-E281-47B4-80D5-F16B7FFB776BQ39646890-ECD71796-541B-4C96-A7B8-C4179B748880Q40637766-8CE2240B-1DA3-4966-A443-CC8A82528E3EQ41096355-6CE0A7AC-B5F1-497A-B6DC-17A5E5F4E3CEQ41463954-01B7F4D2-3BA9-4F0D-B3F5-F23E0D6253CEQ43760328-D2E62F96-8EBB-48C1-9642-CFFC95E9E6EDQ45872326-98569A2C-8700-49DE-8954-9832D698C718Q46799300-ACF60E45-70D8-4CDF-AC82-4DB6B1F4488EQ47725947-D7FB21A3-0C2B-4834-88A9-D791A129A97AQ49954115-5A9E6F58-1089-4A64-B65A-325E0CB7D248Q51525609-3A7045F9-2B6D-4023-B697-F8121BCB67BBQ52234534-DD80C56F-3562-41F8-91F2-CEC6363743D6Q54065301-E59E497E-0B7E-46F6-AFE4-253B92E280C3
P2860
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Urokinase-type plasminogen act ...... py in recurrent breast cancer.
@ast
Urokinase-type plasminogen act ...... py in recurrent breast cancer.
@en
type
label
Urokinase-type plasminogen act ...... py in recurrent breast cancer.
@ast
Urokinase-type plasminogen act ...... py in recurrent breast cancer.
@en
prefLabel
Urokinase-type plasminogen act ...... py in recurrent breast cancer.
@ast
Urokinase-type plasminogen act ...... py in recurrent breast cancer.
@en
P2093
P356
P1476
Urokinase-type plasminogen act ...... py in recurrent breast cancer.
@en
P2093
P304
P356
10.1093/JNCI/87.10.751
P407
P577
1995-05-01T00:00:00Z